Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
21 June 2019Website:
http://immunovant.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 22:08:10 GMTDividend
Analysts recommendations
Institutional Ownership
IMVT Latest News
NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2024.
Biohaven stock crashed Wednesday after the company's experimental protein-degrading drug lagged investor expectations.
On Wall Street, analysts have set an average price target for Immunovant (IMVT) that suggests a potential increase of 68.6%. Although the reliability of this metric is uncertain, the positive trend in earnings estimates could lead to a rise in the stock price.
There is increasing optimism about Immunovant's earnings prospects, leading to its upgrade to a Zacks Rank #2 (Buy) and potentially causing the stock to rise.
Immunovant's IMVT-1402 shows promise for at-home autoimmune treatment, with a differentiated subcutaneous delivery. Phase 1 data indicate significant IgG reductions without major side effects, advancing toward registrational trials. Financial health appears strong with a 40-month cash runway, but increased R&D could affect this.
Immunovant, Inc. (IMVT) reported earnings 30 days ago. What's next for the stock?
The heavy selling pressure might have exhausted for Immunovant, Inc. (IMVT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.
Immunovant (IMVT) announces positive initial data from the mid-stage study of batoclimab in patients with Graves' disease. The stock gains 12% in the after-market hours, following the news.
Immunovant (IMVT) posts encouraging initial results from the 600 mg MAD cohort of its early-stage study on IMVT-1402. Stock rises.
- 1(current)
What type of business is Immunovant?
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
What sector is Immunovant in?
Immunovant is in the Healthcare sector
What industry is Immunovant in?
Immunovant is in the Biotechnology industry
What country is Immunovant from?
Immunovant is headquartered in United States
When did Immunovant go public?
Immunovant initial public offering (IPO) was on 21 June 2019
What is Immunovant website?
https://immunovant.com
Is Immunovant in the S&P 500?
No, Immunovant is not included in the S&P 500 index
Is Immunovant in the NASDAQ 100?
No, Immunovant is not included in the NASDAQ 100 index
Is Immunovant in the Dow Jones?
No, Immunovant is not included in the Dow Jones index
When does Immunovant report earnings?
The next expected earnings date for Immunovant is 09 August 2024